A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

导出原文传递

翻译打印收藏纠错

作者： Gordon,M.S. ^[1] ; Rosen,L.S. ^[2] ; Mendelson,D. ^[3] ; Ramanathan,R.K. ^[4] ; Goldman,J. ^[5] ; Liu,L. ^[6] ; Xu,Y. ^[7] ; Gerson,S.L. ; Anthony,S.P. ; Figg,W.D. ; Spencer,S. ; Adams,B.J. ; Theuer,C.P. ; Leigh,B.R. ; Weiss,G.J.

作者单位： TRACON Pharmaceuticals, San Diego, CA, United States ^[1] Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare (VGPCC), TGen, Scottsdale ^[2] Frederick National Laboratory for Cancer Research, Center for Cancer Research, National Cancer ^[3] Los Angeles Division of Hematology-Oncology, University of California, Santa Monica, CA, United ^[4] Pinnacle Oncology Hematology, 9055 E. Del Camino, Scottsdale, AZ 85258, United States ^[5] Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, United States, Case ^[6] Evergreen Hematology and Oncology, Spokane, WA, United States ^[7]

关键词 Base excision repair First-in-human Methoxyamine Pemetrexed Phase 1 TRC102

发布时间 2014-02-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交